Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 12/20 | 0.53 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.43 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28786496 | 0.89 | GLP1R (0.43) | GLP1RMAP4K4HDAC1GPR119SUV39H2 | |
| SCHEMBL28786493 | 0.89 | GLP1R (0.43) | GLP1RMAP4K4HDAC1GPR119SUV39H2 | |
| SCHEMBL20266505 | 0.89 | GLP1R (0.58) | GLP1R | |
| SCHEMBL20266503 | 0.89 | GLP1R (0.58) | GLP1R | |
| SCHEMBL24320732 | 0.88 | GLP1R (0.54) | GLP1RMAP4K4 | |
| SCHEMBL28546320 | 0.88 | MAP4K4 (0.47) | GLP1RMAP4K4HDAC1GPR119SUV39H2 | |
| SCHEMBL30662678 | 0.88 | GPR119 (0.49) | GLP1RMAP4K4HDAC1GPR119SUV39H2 | |
| SCHEMBL30269669 | 0.88 | MAP4K4 (0.47) | GLP1RMAP4K4HDAC1GPR119SUV39H2 | |
| SCHEMBL24320504 | 0.86 | GPR119 (0.49) | GLP1RMAP4K4GPR119SUV39H2 | |
| SCHEMBL24320310 | 0.85 | NR1H2 (0.47) | MAP4K4HDAC1GPR119SUV39H2NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250257052-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | PFIZER INC. (US) | 2025-08-14 | — | — | US | disclosed |
| US-12319669-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2025-06-03 | — | — | US | disclosed |
| US-20240034725-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | PFIZER INC. (US) | 2024-02-01 | — | — | US | disclosed |
| US-11802121-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-20230124938-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | PFIZER INC. (US) | 2023-04-20 | — | — | US | disclosed |
| EP-3555064-B9 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | PFIZER (US) | 2023-03-01 | — | — | EP | disclosed |
| US-11512070-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2022-11-29 | — | — | US | disclosed |
| EP-3555064-B1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | PFIZER (US) | 2022-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11512070-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GPR119 | GLP1R 1/4885MAP4K4 1348/4885HDAC1 530/4885 |
| US-20250257052-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | GLP1R, GIPR, GPR119 | GLP1R 1/4885MAP4K4 1348/4885HDAC1 530/4885 |
| US-12319669-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GPR119 | GLP1R 1/4885MAP4K4 1348/4885HDAC1 530/4885 |
| US-11802121-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GPR119 | GLP1R 1/4885MAP4K4 1348/4885HDAC1 530/4885 |
| US-20240034725-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | GLP1R, GIPR, GPR119 | GLP1R 1/4885MAP4K4 1348/4885HDAC1 530/4885 |
| US-20230124938-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | GLP1R, GIPR, GPR119 | GLP1R 1/4885MAP4K4 1348/4885HDAC1 530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.